Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder

Charles L. Bowden

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Although monotherapy with lithium or divalproex is the recommended initial therapy for bipolar disorder, these agents are associated with prolonged favorable outcomes in only 30% of patients. Increasingly, the medical literature is demonstrating that augmentation of mood stabilizers with atypical antipsychotics is a more effective therapy. This form of combination therapy is recommended as first-line treatment for severe bipolar mania. Recent clinical studies have shown that augmentation therapy with the atypical antipsychotics risperidone, olanzapine, quetiapine, and ziprasidone is effective in long-term maintenance treatment, and preliminary evidence is emerging that use of atypicals with mood stabilizers can help control the depressive phase of bipolar disorder. The atypical antipsychotics also have relatively mild side effect profiles, although augmentation therapy with some antipsychotics and mood stabilizers has been associated with excessive weight gain.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalJournal of Clinical Psychiatry
Issue numberSUPPL. 3
StatePublished - Apr 18 2005

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder'. Together they form a unique fingerprint.

Cite this